Cargando…

Inhibition of Cdk5 induces cell death of tumor-initiating cells

BACKGROUND: Tumour-initiating cells (TICs) account for chemoresistance, tumour recurrence and metastasis, and therefore represent a major problem in tumour therapy. However, strategies to address TICs are limited. Recent studies indicate Cdk5 as a promising target for anti-cancer therapy and Cdk5 ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandl, Melanie M, Zhang, Siwei, Ulrich, Melanie, Schmoeckel, Elisa, Mayr, Doris, Vollmar, Angelika M, Liebl, Johanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379151/
https://www.ncbi.nlm.nih.gov/pubmed/28222068
http://dx.doi.org/10.1038/bjc.2017.39
_version_ 1782519551441764352
author Mandl, Melanie M
Zhang, Siwei
Ulrich, Melanie
Schmoeckel, Elisa
Mayr, Doris
Vollmar, Angelika M
Liebl, Johanna
author_facet Mandl, Melanie M
Zhang, Siwei
Ulrich, Melanie
Schmoeckel, Elisa
Mayr, Doris
Vollmar, Angelika M
Liebl, Johanna
author_sort Mandl, Melanie M
collection PubMed
description BACKGROUND: Tumour-initiating cells (TICs) account for chemoresistance, tumour recurrence and metastasis, and therefore represent a major problem in tumour therapy. However, strategies to address TICs are limited. Recent studies indicate Cdk5 as a promising target for anti-cancer therapy and Cdk5 has recently been associated with epithelial–mesenchymal transition (EMT). However, a role of Cdk5 in TICs has not been described yet. METHODS: Expression of Cdk5 in human cancer tissue was analysed by staining of a human tissue microarray (TMA). Functional effects of Cdk5 overexpression, genetic knockdown by siRNA and shRNA, and pharmacologic inhibition by the small molecule roscovitine were tested in migration, invasion, cell death, and tumorsphere assays and in tumour establishment in vivo. For mechanistic studies, molecular biology methods were applied. RESULTS: In fact, here we pin down a novel function of Cdk5 in TICs: knockdown and pharmacological inhibition of Cdk5 impaired tumorsphere formation and reduced tumour establishment in vivo. Conversely, Cdk5 overexpression promoted tumorsphere formation which was in line with increased expression of Cdk5 in human breast cancer tissues as shown by staining of a human TMA. In order to understand how Cdk5 inhibition affects tumorsphere formation, we identify a role of Cdk5 in detachment-induced cell death: Cdk5 inhibition induced apoptosis in tumorspheres by stabilizing the transcription factor Foxo1 which results in increased levels of the pro-apoptotic protein Bim. CONCLUSIONS: In summary, our study elucidates a Cdk5-Foxo1-Bim pathway in cell death in tumorspheres and suggests Cdk5 as a potential target to address TICs.
format Online
Article
Text
id pubmed-5379151
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53791512018-03-28 Inhibition of Cdk5 induces cell death of tumor-initiating cells Mandl, Melanie M Zhang, Siwei Ulrich, Melanie Schmoeckel, Elisa Mayr, Doris Vollmar, Angelika M Liebl, Johanna Br J Cancer Translational Therapeutics BACKGROUND: Tumour-initiating cells (TICs) account for chemoresistance, tumour recurrence and metastasis, and therefore represent a major problem in tumour therapy. However, strategies to address TICs are limited. Recent studies indicate Cdk5 as a promising target for anti-cancer therapy and Cdk5 has recently been associated with epithelial–mesenchymal transition (EMT). However, a role of Cdk5 in TICs has not been described yet. METHODS: Expression of Cdk5 in human cancer tissue was analysed by staining of a human tissue microarray (TMA). Functional effects of Cdk5 overexpression, genetic knockdown by siRNA and shRNA, and pharmacologic inhibition by the small molecule roscovitine were tested in migration, invasion, cell death, and tumorsphere assays and in tumour establishment in vivo. For mechanistic studies, molecular biology methods were applied. RESULTS: In fact, here we pin down a novel function of Cdk5 in TICs: knockdown and pharmacological inhibition of Cdk5 impaired tumorsphere formation and reduced tumour establishment in vivo. Conversely, Cdk5 overexpression promoted tumorsphere formation which was in line with increased expression of Cdk5 in human breast cancer tissues as shown by staining of a human TMA. In order to understand how Cdk5 inhibition affects tumorsphere formation, we identify a role of Cdk5 in detachment-induced cell death: Cdk5 inhibition induced apoptosis in tumorspheres by stabilizing the transcription factor Foxo1 which results in increased levels of the pro-apoptotic protein Bim. CONCLUSIONS: In summary, our study elucidates a Cdk5-Foxo1-Bim pathway in cell death in tumorspheres and suggests Cdk5 as a potential target to address TICs. Nature Publishing Group 2017-03-28 2017-02-21 /pmc/articles/PMC5379151/ /pubmed/28222068 http://dx.doi.org/10.1038/bjc.2017.39 Text en Copyright © 2017 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Translational Therapeutics
Mandl, Melanie M
Zhang, Siwei
Ulrich, Melanie
Schmoeckel, Elisa
Mayr, Doris
Vollmar, Angelika M
Liebl, Johanna
Inhibition of Cdk5 induces cell death of tumor-initiating cells
title Inhibition of Cdk5 induces cell death of tumor-initiating cells
title_full Inhibition of Cdk5 induces cell death of tumor-initiating cells
title_fullStr Inhibition of Cdk5 induces cell death of tumor-initiating cells
title_full_unstemmed Inhibition of Cdk5 induces cell death of tumor-initiating cells
title_short Inhibition of Cdk5 induces cell death of tumor-initiating cells
title_sort inhibition of cdk5 induces cell death of tumor-initiating cells
topic Translational Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379151/
https://www.ncbi.nlm.nih.gov/pubmed/28222068
http://dx.doi.org/10.1038/bjc.2017.39
work_keys_str_mv AT mandlmelaniem inhibitionofcdk5inducescelldeathoftumorinitiatingcells
AT zhangsiwei inhibitionofcdk5inducescelldeathoftumorinitiatingcells
AT ulrichmelanie inhibitionofcdk5inducescelldeathoftumorinitiatingcells
AT schmoeckelelisa inhibitionofcdk5inducescelldeathoftumorinitiatingcells
AT mayrdoris inhibitionofcdk5inducescelldeathoftumorinitiatingcells
AT vollmarangelikam inhibitionofcdk5inducescelldeathoftumorinitiatingcells
AT liebljohanna inhibitionofcdk5inducescelldeathoftumorinitiatingcells